The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects

Abstract

The use of immunotherapy to treat cancer is rapidly gaining momentum. Using pre-clinical mouse models, we have recently demonstrated potent and long lasting tumor regression can be elicited by immune-stimulating monoclonal antibodies (mAbs) when combined with histone deacetylase inhibitors (HDACi) and believe this therapy will have broad application in humans. © 2012 Landes Bioscience.